Clinical trials: Chronic Diseases
Cerebral Palsy (CP)
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function
- Trial name
- NCT01468350
- Testing
- dalfampridine-ER 10mg
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Acorda Therapeutics
Coronary Occlusion
Safety and Efficacy of the CiTop™ Guidewire for Crossing Chronic Total Occlusions in Coronary Arteries
The CiTop™ guidewire Coronary study is a feasibility open label study, to evaluate the safety and efficacy of the CiTop™ Guidewire for crossing chronic total occlusion in Coronary arteries.
- Trial name
- NCT00618020
- Testing
- CiTop(tm) Guidewire
- Where
- India
- Volunteers
- 10 people
- Sponsor
- Ovalum
Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background…
- Trial name
- Eluminate-4 (NCT07662135)
- Testing
- Elecoglipron
- Where
- 186 sites in United States, Bulgaria and 14 more
- Volunteers
- 900 people
- Sponsor
- AstraZeneca
Hyperphosphatemia, Kidney Disease
Fosrenol Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan and it is a local prospective and observational study of patients who have received Fosrenol.
- Trial name
- NCT01955876
- Testing
- Lanthanum Carbonate (Fosrenol, BAY77-1931)
- Where
- Japan
- Volunteers
- 343 people
- Sponsor
- Bayer
Chronic Myelogenous Leukemia
A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients
Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib in accelerated or blastic Phase chronic myelogenous leukemia patients.
- Trial name
- NCT02511340
- Testing
- Flumatinib mesylate tablet 600 mg qd
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pulmonary Disease, Chronic Obstructive
A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects
The purpose of this study is to evaluate the effects on lung function of a combination of ADOAIR 50/250mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatments (tiotropium bromide 18mcg…
- Trial name
- SCO116572 (NCT01751113)
- Testing
- fluticasone propionate/salmeterol, tiotropium bromide, fluticasone propionate/salmeterol plus tiotropium bromide
- Where
- 3 sites in Japan
- Volunteers
- 53 people
- Sponsor
- GlaxoSmithKline
Anemia
A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis
This single-arm study will assess the efficacy and safety of monthly administration of intravenous methoxy polyethylene glycol-epoetin beta (CERA/Mircera) for the maintenance of hemoglobin (Hb) levels in participants on dialysis…
- Trial name
- NCT00660023
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 10 sites in Hungary
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study was to determine whether potentiating the cystic fibrosis transmembrane conductance regulator (CFTR) with QBW251 in subjects with COPD would be efficacious with regards to reducing lung and systemic…
- Trial name
- NCT04268823
- Testing
- QBW251
- Where
- 12 sites in Austria, Germany and 2 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
Primary Objective: To evaluate the efficacy of dupilumab 300 milligram (mg) every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity…
- Trial name
- SINUS-24 (NCT02912468)
- Testing
- Dupilumab SAR231893 (REGN668), Mometasone furoate 50 micrograms
- Where
- 76 sites in United States, Bulgaria and 11 more
- Volunteers
- 276 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 compared to placebo and Formoterol Fumarate (Foradil Aerolizer) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00880490
- Testing
- Inhaled PT005, Formoterol Fumarate 12 mcg (Foradil Aerolizer)
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 34 people
- Sponsor
- Pearl Therapeutics, Inc.
11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL)
AZD6738 First Time in Patient Multiple Ascending Dose Study
In Part A to investigate the safety and tolerability of AZD6738 when given orally to patients with relapsed/refractory CLL, PLL or B cell lymphoma.
- Conditions
- 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
- Trial name
- NCT01955668
- Testing
- Administration of AZD6738
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Endotoxin Challenge Study For Healthy Men and Women
The proposed study will examine the effect of pre-treatment with inhaled GSK256066 using a lung inflammation model induced by bronchoscopic instillation of bacterial endotoxin (lipopolysaccharide, LPS) in healthy volunteers.Data…
- Trial name
- NCT00515268
- Testing
- GSK256066
- Where
- Germany
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
The purpose of this study is to further assess the safety of dasatinib in imatinib intolerant or resistant patients with chronic phase chronic myeloid leukemia, advanced phase chronic myeloid leukemia or Philadelphia chromosome…
- Trial name
- NCT00349518
- Testing
- Dasatinib
- Where
- 20 sites in Hungary, Italy and 4 more
- Sponsor
- Bristol-Myers Squibb
Purpura, Thrombocytopenic, Idiopathic
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
This was an open-label Phase III extension study to evaluate the long-term safety of eltrombopag in pediatric patients with chronic ITP who previously participated in study TRA115450.
- Trial name
- NCT02201290
- Testing
- Eltrombopag Tablets, Eltrombopag PfOS
- Where
- 3 sites in Russia
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients
This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin.
- Trial name
- NCT00077610
- Testing
- Epoetin alfa or beta, RO0503821 (1x/2 Weeks), RO0503821 (1x/4 Weeks)
- Where
- 99 sites in United States, Canada and 6 more
- Volunteers
- 673 people
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease (COPD)
Validation of Structured Light Plethysmography - Health and Disease
Validation of Structured Light Plethysmography (SLP) in patients with conditions such as Chronic Obstructive Pulmonary Disease (COPD) that effect breathing and in healthy participants.
- Trial name
- SLP-RespDis (NCT02626468)
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pneumacare Ltd
Diabetic Chronic Kidney Disease
A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes
A phase 2b, placebo-controlled, randomized, double-blind, multi-center study of GCS-100 in patients with chronic kidney disease caused by diabetes.
- Trial name
- NCT02312050
- Testing
- GCS-100
- Where
- 8 sites in United States
- Volunteers
- 375 people
- Sponsor
- La Jolla Pharmaceutical Company
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
- Trial name
- NCT02680574
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 503 sites in United States, Argentina and 28 more
- Volunteers
- 1,725 people
- Sponsor
- Akebia Therapeutics
Plaque Psoriasis
Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis
This study is designed to evaluate the efficacy and safety of Prurisol using three different oral daily dose regimens administered to subjects with active mild to moderate chronic plaque psoriasis.
- Trial name
- NCT02494479
- Testing
- Prurisol
- Where
- 9 sites in United States
- Volunteers
- 115 people
- Sponsor
- Cellceutix Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.